R&D channel feed

Shang­hai star­tup's gene ther­a­py re­stores hear­ing in five deaf chil­dren, run­ning ahead of Lil­ly and Re­gen­eron tri­als

Last year
Cell/Gene Tx

Roche and Ex­elix­is de­tail rare suc­cess for Cabome­tyx-Tecen­triq com­bo in prostate can­cer

Last year
Pharma

Eli Lil­ly says its po­ten­tial gene ther­a­py 're­stored hear­ing' in 11-year-old boy

Last year
Cell/Gene Tx

Sanofi wades in­to AATD in $1.7B bid for In­hi­brx's rare dis­ease drug

Last year
Deals

Io­n­is touts PhI­II suc­cess for rare dis­ease drug amid com­pa­ny's push to com­mer­cial­ize drugs in­de­pen­dent­ly

Last year

Lack­lus­ter da­ta on Alzheimer's drugs lead to end of Roche-AC Im­mune part­ner­ship

Last year
Deals
Pharma

Trodelvy fails PhI­II lung can­cer study in blow to Gilead’s ADC ex­pan­sion plans

Last year

Hi­ber­na­tion re­search could lead to new weight loss med­i­cines — could it al­so help as­tro­nauts in space?

Last year
Deals

As­traZeneca's Imfinzi com­bo ex­tends PFS in liv­er can­cer; No­var­tis shares new de­tails about Lu­tather­a's PhI­II

Last year

Af­ter Bris­tol My­ers pulls out of col­lab­o­ra­tion, Ike­na On­col­o­gy lays off 35% of staff and trims can­cer pipeline

Last year
People

CAR NK ther­a­py looks durable in a small tri­al, giv­ing in­sight in­to large Take­da study

Last year
Cell/Gene Tx

Up­dat­ed: No­var­tis ax­es PhI­II peanut al­ler­gy tri­al, ex­pects to test 'op­ti­mized dos­ing' in new tri­al lat­er this year

Last year

Roche's TIG­IT win lim­it­ed by stan­dard of care change, lack of glob­al study

Last year

Re­genxbio touts pos­i­tive mid-stage da­ta for Ab­b­Vie-part­nered vi­sion-loss gene ther­a­py, but no de­tailed plans for piv­otal study

Last year
Cell/Gene Tx

Mer­ck adds third cer­vi­cal can­cer nod for Keytru­da, bring­ing to­tal ap­provals to 39

Last year
Pharma

Look­ing past COPD, Re­gen­eron CSO George Yan­copou­los says Dupix­en­t's 'next big thing' is re­vers­ing al­ler­gies

Last year

Al­lakos halves work­force, drops lead in­flam­ma­to­ry pro­gram

Last year
People

Dyne clos­es $345M pub­lic of­fer­ing a week af­ter ear­ly pos­i­tive da­ta for dy­s­tro­phy drugs

Last year
Financing

Greg Ver­dine’s LifeM­ine eyes the clin­ic next year with T-cell im­muno­sup­pres­sive and an­ti­fun­gal: #JPM24

Last year
Startups

#JPM24 quick hits: Io­n­is on part­ner­ship’s pros and cons; No­vo Ven­tures has $600M to spend; Are small mol­e­cules back? + more

Last year

Sanofi says it may look at next gen­er­a­tion of weight loss drugs: #JPM24

Last year
Pharma

Af­ter 'grow­ing up' last year, Mod­er­na warns of loss­es and charts path back to prof­its: #JPM24

Last year
Pharma

Co­herus ex­its TIG­IT deal with Jun­shi, three months af­ter Sur­face On­col­o­gy buy­out

Last year
Deals

C4 Ther­a­peu­tics cuts staff, re­struc­tures to fo­cus on lead pro­tein degra­da­tion pro­grams, dis­cov­ery pacts

Last year
People
First page Previous page 54555657585960 Next page Last page
A service from the Financial Times